To evaluate the potential use and scalability of MN-anti-miR10b for preclinical drug testing we embarked on the first feline patient case study (Cat 0 in Figure 1) with HER2+ primary and metastatic tumors (Supplementary Figure 3A). Here, ERBB2 is linked to metastatic neoplasm.